Anteris Technologies (AU:AVR) has released an update.
Anteris Technologies Ltd has dispatched the Scheme Booklet to its shareholders and optionholders, detailing instructions for the upcoming Extraordinary General Meeting and Scheme Meetings scheduled for October 4, 2024. The materials, including an Independent Expert’s Report, are available on the company’s website, and stakeholders are encouraged to participate and vote in person or through provided proxy forms. Anteris is a structural heart company with a focus on developing medical devices, including a bioengineered transcatheter heart valve aimed at addressing aortic stenosis.
For further insights into AU:AVR stock, check out TipRanks’ Stock Analysis page.
